The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study
The frequency and reasons for antiretroviral switching with specific antiretroviral associations: The SWITCH study
复制标题
DOI：
10.1016/j.antiviral.2010.03.001
复制
发表时间：
2010-05-01
影响因子：
7.6
通讯作者：
Stebbing, J.
中科院分区：
文献类型：
--
作者：
Davidson, I.;Beardsell, H.;Stebbing, J.
背景资料：我们调查的原因切换抗逆转录病毒治疗方案，一个问题很少解决在队列study.Methods：观察到的毒性转换率（OTSR）计算泊松回归使用的天数个人收到每个人的抗逆转录病毒drug.Results：3333个人接受HAART，共有14%的方案转换，大多数发生在6个月的治疗。毒性是转换的主要原因（61%），基于蛋白酶抑制剂（OTSR 26.4，95% CI 18.3-37）和非核苷类逆转录酶抑制剂（OTSR 22.2，95% CI 13.6-34.4）的方案之间的OTSR无重大统计学显著差异。对于个别抗逆转录病毒药物，司他夫定和齐多夫定有显着较高的“开关”分数比所有其他drugs.Conclusions：有主要HAART类OTSR之间没有差异。我们认为，较新的抗逆转录病毒药物需要在长期毒性方面进行区分，因为这是转换的主要原因。(C)2010 Elsevier B. V.保留所有权利。
Background: We investigated the reasons for switching antiretroviral regimens, an issue rarely addressed in cohort studies.Methods: An observed toxicity switch rate (OTSR) was calculated by Poisson regression using the number of days individuals received each individual antiretroviral drug.Results: Of 3333 individuals receiving HAART, a total of 14% of regimens were switched, the majority occurring after 6 months of therapy. Toxicity was the major reason for switching (61%) and there were no major statistically significant differences in OTSR between the protease inhibitor (OTSR 26.4, 95% CI 18.3-37) and non-nucleoside reverse transcriptase inhibitor (OTSR 22.2,95% CI 13.6-34.4) based regimes. For individual antiretrovirals, stavudine and zidovudine had significantly higher "switch" scores than all other drugs.Conclusions: There were no differences between the major HAART classes in OTSR. We suggest that newer antiretrovirals will require differentiation in terms of longer-term toxicity, as this is the major reason for switching. (C) 2010 Elsevier B.V. All rights reserved.